Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Migraine With Aura Clear all

Conditions: Migraine With and Without Aura, Chronic Migraine, Healthy Controls
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine, Aura, Patent Foramen Ovale
Interventions: BioSTAR Septal Repair Implant System, Sham Procedure; Device · Procedure
Lead sponsor: NMT Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Stamford, Connecticut • Seattle, Washington

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant, Usual Care; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 1,254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 177
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Migraine Headache, With or Without Aura
Interventions: Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Mount Vernon, New York

Conditions: Migraine
Interventions: Diclofenac Potassium for Oral Solution; Drug
Lead sponsor: Depomed; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Tampa, Florida • Amherst, New York

Conditions: Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions: Rimegepant, Zavegepant; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Migraine With or Without Aura
Interventions: Low-Dose Naltrexone and Acetaminophen Combination, Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Migraine With Aura
Interventions: Active Transcranial Magnetic Stimulation (TMS) Device, Sham TMS Device; Device
Lead sponsor: Neuralieve; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 11 more

Conditions: Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions: milnacipran; Drug
Lead sponsor: California Medical Clinic for Headache; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Migraine With Aura
Interventions: Partial Rebreathing Device, Sham breathing device; Device
Lead sponsor: Rehaler; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Palo Alto, California • Pasadena, California • Riverside, California + 6 more

Conditions: Migraine
Interventions: DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C); Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 138
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Acute Migraine With or Without Aura
Interventions: sumatriptan nasal powder, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Migraine, Headaches
Interventions: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more

Conditions: Migraine Disorders, Headache, Migraine, Migraine, Migraine Headache, Migraine With Aura, Migraine Without Aura, Headache Disorders, Primary
Interventions: Triptan, Doxycycline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 98
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 86 more

Conditions: Tinnitus
Interventions: Nortriptyline, Topiramate, Paroxetine, Verapamil; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 25 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Orange, California

Conditions: Migraine
Interventions: EVO756, Dose 1, EVO756, Dose 2, Placebo; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Chandler, Arizona • Buena Park, California • Fresno, California + 31 more

Conditions: Migraine Disorders
Interventions: sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 49
States / cities: Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Episodic Migraine, Chronic Migraine
Interventions: Aspirin (acetylsalicylic acid), Placebo; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine Without Aura, Migraine With Aura
Interventions: Nerivio Migra-1 active device, Nerivio Migra-1 Sham device; Device
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more

Search by objective public record fields.

Migraine and Body Composition

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Staccato Prochlorperazine in Migraine (in Clinic)

Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura

Preventive Treatment of Episodic and Chronic Migraine

PArtial REbreathing for Migraine With Aura 1

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine

Open Label Safety Study in Acute Treatment of Migraine

Management of Acute Tinnitus With Migraine Medications

Study of EVO756 in Adults With Migraine

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Aspirin Resistance in Women With Migraine

Evaluation of a Novel Device for Treatment of Migraine Headache

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine